dc.contributor.author | Dorward, Jienchi | |
dc.contributor.author | Gbinigie, Kome | |
dc.date.accessioned | 2020-04-20T14:26:07Z | |
dc.date.available | 2020-04-20T14:26:07Z | |
dc.date.issued | 2020-04-14 | |
dc.identifier.uri | https://www.cebm.net/covid-19/lopinavir-ritonavir-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid/ | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1087 | |
dc.description.abstract | There are currently no pharmacological treatments for COVID-19. Due to the urgent need for effective treatments, there has been increased interest in re-purposing currently available drugs for immediate use. The antiretroviral drug lopinavir is a protease inhibitor, which is widely used for the treatment of HIV and is a potential candidate for the treatment of COVID-19. Lopinavir is formulated in combination with another protease inhibitor, ritonavir (lopinavir/ritonavir, branded as Kaletra or Aluvia). Ritonavir inhibits the metabolising enzyme cytochrome P450 3A and therefore increases the half-life of lopinavir. There are some preliminary evidence of the effectiveness of lopinavir/ritonavir against other coronaviruses. In vivo, an open-label, non-randomised study found a reduced risk of severe hypoxia or death in 41 SARS-CoV patients who were treated with lopinavir/ritonavir and ribavirin, compared to 111 historical controls treated with ribavirin alone. There has been no evidence from randomised trials of the efficacy of lopinavir/ritonavir in treating SARS-CoV or MERS-CoV. We review the evidence for the use of lopinavir/ritonavir (LPVr) as a treatment for COVID-19. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Lopinavir | en_US |
dc.subject | Ritonavir | en_US |
dc.subject | Protease Inhibitors | en_US |
dc.title | Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 | en_US |
eihealth.country | Others | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Research protocol information | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |